---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-129417"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:30:53.763732+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Assertio appoints Schwichtenberg as CTO, Pietryga as CCO, Reisenauer to board

## Summary
- Paul Schwichtenberg (formerly CCO, CFO) named Chief Transformation Officer effective Dec 16, 2024, focusing on growth and new revenue strategies.
- Mary Pietryga appointed Chief Commercial Officer effective Dec 16, 2024, overseeing sales, marketing, and access.
- Mark Reisenauer, former President US Commercial at Astellas, appointed to board effective Jan 2, 2025, also joining Compensation Committee.
- Pietryga joins from Teva Pharmaceuticals as VP and Head of Global Biosimilar Portfolio.

## SEC filing metadata
- accession: 0001104659-24-129417
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000110465924129417/0001104659-24-129417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000110465924129417/tm2430960d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-129417
- JSON: https://secwatch.observer/filing/0001104659-24-129417.json
- Plain text: https://secwatch.observer/filing/0001104659-24-129417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.